- Conditions
- Type 1 Diabetes
- Interventions
- MPC closed-loop system in insulin only mode, MPC closed-loop system in insulin/pramlintide mode
- Device
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Portland, Oregon
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 1,804
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Placebo, 100 mg PF-05231023
- Other · Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 2
- States / cities
- Orlando, Florida
- Conditions
- Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
- Interventions
- MiniMed™ NMX8-AID System with DS5™/Simplera Sync™
- Device
- Lead sponsor
- Medtronic MiniMed, Inc.
- Industry
- Eligibility
- 7 Years to 85 Years
- Enrollment
- 389 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 29
- States / cities
- Little Rock, Arkansas • Escondido, California • Goleta, California + 25 more
- Conditions
- Eating Disorders, Type 1 Diabetes
- Interventions
- Diabetes Body Project, Educational Control
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 15 Years to 30 Years · Female only
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases
- Interventions
- GFB-024, Placebo
- Drug
- Lead sponsor
- Goldfinch Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hypoglycemia
- Interventions
- G-Pen Mini™ (glucagon injection)
- Drug
- Lead sponsor
- Xeris Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- IcoSema, Semaglutide 1 mg
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 683 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 1 Year to 35 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Aurora, Colorado • Tallahassee, Florida • Philadelphia, Pennsylvania + 2 more
- Conditions
- Type 1 Diabetes Mellitus, Hypoglycemia
- Interventions
- Allogeneic islets of Langerhans transplant, Raptiva, Sirolimus, anti-thymocyte globulin
- Biological · Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Stage 3 Type 1 Diabetes
- Interventions
- AutoCD6-CAR Treg cells
- Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Type 1 Diabetes Mellitus, Hypoglycemia
- Interventions
- Allogeneic Islets of Langerhans
- Biological
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Viaject 7, LISPRO
- Drug
- Lead sponsor
- Biodel
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Chronic Kidney Diseases
- Interventions
- CLBS201
- Drug
- Lead sponsor
- Lisata Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 1 Diabetes
- Interventions
- Metformin, Placebo
- Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- MEDI0382 Formulation 2, MEDI0382 Formulation 3
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin Degludec, Insulin Glargine, TRESIBA® FLEXTOUCH®, LANTUS® SOLOSTAR® INSULIN PEN
- Drug · Device
- Lead sponsor
- Sansum Diabetes Research Institute
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Santa Barbara, California • Honolulu, Hawaii
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- MYL-1501D product using manufacture process V, MYL-1501D product using manufacture process VI
- Drug
- Lead sponsor
- Mylan Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 38
- States / cities
- Fresno, California • Greenbrae, California • Huntington Beach, California + 33 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 8
- States / cities
- Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more
- Conditions
- Type 1 Diabetes
- Interventions
- Multiple daily ijnection using Insulin Degludec and Insulin Aspart
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Asthma, Diabetes Mellitus
- Interventions
- Inhaled Insulin, Subcutaneous Insulin
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 86
- States / cities
- Glendale, Arizona • Peoria, Arizona • Phoenix, Arizona + 64 more
- Conditions
- Type 1 Diabetes
- Interventions
- There is no intervention
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 12 Years to 55 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Diabetic Ketoacidosis, Uncontrolled Type 1 Diabetes Mellitus
- Interventions
- Not listed
- Lead sponsor
- Children's Hospitals and Clinics of Minnesota
- Other
- Eligibility
- 7 Years to 18 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Minneapolis and Saint Paul, Minnesota
- Conditions
- Type 1 Diabetes
- Interventions
- Co-transplantation of PTG with pancreatic islets
- Combination Product
- Lead sponsor
- Peter Stock
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- family diabetes management intervention
- Behavioral
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 108 Months to 174 Months
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 4
- States / cities
- Jacksonville, Florida • Chicago, Illinois • Boston, Massachusetts + 1 more